This systematic review and meta-analysis compares the incidence and risk of endocrine adverse events following treatment with US Food and Drug Administration-approved immune checkpoint inhibitor regimens.
from Cancer via ola Kala on Inoreader http://ift.tt/2fttnc6
via IFTTT
Cancer Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου